MAXAIR
LOE ApproachingNDAINHALATIONAEROSOL, METERED
Approved
Dec 1986
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 14h ago · AI intelligence enriched 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MAXAIR is a metered-dose aerosol inhaler approved in 1986 for inhalation use. The specific indication and mechanism of action are not provided in available data, but the inhalation route and aerosol formulation suggest a respiratory therapy application. This is a small-molecule NDA product from Bausch + Lomb.
LOE Approaching
As an aging product approaching loss of exclusivity with moderate competitive pressure (30 out of 100), the MAXAIR brand team is likely focused on lifecycle management and optimization rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on MAXAIR offers limited growth prospects due to its LOE-approaching status and lack of linked job openings. Professionals joining this team should expect focus on defending market share, managing pricing pressures, and potentially transitioning to other pipeline assets.
Brand ManagerProduct Manager
Worked on MAXAIR at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.